Tariff-related Litigation Update – 7/25
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 25, 2025.
Tariffs
Stay up to date on tariff policies that impact your global operations. This section provides insights on trade developments, regulatory changes, and AdvaMed’s advocacy to minimize tariff burdens on medtech manufacturers and maintain global supply chain stability.
Tariff-related Litigation Update – 7/18
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 18, 2025.
AdvaMed® Advancements: Q2 2025 Report
Discover our Q2 report highlighting key industry wins, tariff updates, and strategic progress driving medtech innovation and advocacy forward.
Tariff-related Litigation Update – 7/11
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through July 11, 2025.
The Kennedy v Braidwood Ruling: What’s Next for MedTech
Join AdvaMed and Reed Smith experts to explore how the Supreme Court’s ACA ruling in Braidwood could shape preventive care and MedTech policy.
Supreme Court’s Decision in Kennedy v. Braidwood Management, Inc.
Explore the impact of the Supreme Court’s decision in Kennedy v. Braidwood on the ACA preventive services mandate and its implications for MedTech policy.
Tariff-related Litigation Update – 6/27
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through June 17, 2025.
Tariff-related Litigation Update – 6/20
Member-only summary of IEEPA “fentanyl” and reciprocal tariffs under EO 14257, plus status of related legal challenges across federal courts through June 17, 2025.
Tariff-related Litigation Update
Explore the latest IEEPA tariff developments and legal challenges, including executive orders on fentanyl tariffs and reciprocal duties affecting global MedTech trade.
Medtech is Essential: Industry Supports Call for Tariff Flexibility
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly,…